IGFBP1 (Insulin Like Growth Factor Binding Protein 1)

Dysregulation of the FOXO1-dependent cellular fate-control network plays a central role in the development of endometriosis. Elucidating the molecular mechanisms governing FOXO1 activity and its nuclear dynamics will be crucial for a comprehensive understanding of disease progression and for the development of novel therapeutic strategies.

P=N/A, N=75, Not yet recruiting, University of Texas Southwestern Medical Center

FRS, a machine learning-derived pathway signature, robustly predicts immunotherapy response and survival in NSCLC. Its integration of FOXO-mediated immune regulation offers a clinically translatable tool for precision oncology.

We established a non-invasive 8-SPCG signature that may serve as a potential predictor for GC prognosis and TME features. SERPINE1 was identified as a promising mediator linking GC progression to CAFs interactions, supporting its further investigation as a therapeutic target.

We developed and validated an immune-related signature for predicting TNBC outcomes and immunotherapy response. This signature reflects underlying immune landscape heterogeneity and provides a crucial method for patient stratification and immunotherapeutic planning.

P=N/A, N=16, Active, not recruiting, Salk Institute for Biological Studies | Recruiting --> Active, not recruiting

RAMRGs serve as useful biomarkers to predict prognosis in LUAD patients, and may guide the immunotherapy regimen.

The nomogram constructed by ER score and clinical features showed good predictive performance on LUAD. This study provided new insights into understanding the role of ER stress in LUAD.

The results suggest that senescence-related determinants are involved in the tumour microenvironment through senescence-related secretory phenotypes and can be used as reliable biomarkers for LUSC immunotherapy and prognosis.

IGFBP1 indicates the promotion of lymph node metastasis in LUAD by facilitating tumor proliferation, invasion, and migration through modulation of the MAPK-ERK signaling pathway. Our findings highlight IGFBP1 as a potential prognostic biomarker, though its therapeutic utility requires validation in preclinical models.

Passage 0 (n=3) organoids were treated with 1000 ng/ml recombinant ovine Interferon Tau (IFNT) or 10 μg/ml progesterone (P4) for 24 hours and analysed by RNASeq to assess hormone responsiveness...Thirty genes were altered by both P4 treatment and IFNT treatment. Organoids were also shown to express conserved microRNAs, and it was possible to culture them in a microfluidics device - making them a useful model for a multitude of potential investigations.

P=N/A, N=216, Active, not recruiting, Tufts University | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Mar 2026